• SEAROG, Advisor, 2019 to 2019, (International)
• FARO, Council Member, 2019 to 2019, (International)

---

• National Project Coordinator, International, 30/01/2018 to 31/12/2021 (RAS 6086 project Strengthening cancer management programmes in RCA states parties through collaboration with national and regional radiation oncology societies)
• HRPP Committee member, Faculty, 02/05/2017 to 01/05/2019
• JKKF Committee member, University Malaya, 06/04/2017 to 05/04/2020 (JKKF)
• Programme Coordinator, University Malaya, 02/09/2016 to 01/09/2017 (Programme Coordinator for Master of Clinical Oncology)
• Quality Manager, University Malaya, 04/07/2016 to 03/07/2017 (DQM Clinical Oncology)
• AJK Penulisan Kurikulum Nasional Sarjana Perubatan Klinikal bagi bidang Onkologi Klinikal, National, 01/01/2016
• Postgraduate Curriculum Working Group, Faculty, 23/09/2014
• Programme Coordinator, Faculty, 01/09/2014 to 01/09/2016
• Quality Manager, Faculty, 01/07/2014 to 01/07/2016
• Ahli Jawatankuasa PPGP, Faculty, 01/10/2013
• Head, Clinical Oncology Unit, Faculty of Medicine, 01/09/2012 to 31/08/2013
• National Project Coordinator for IAEA project RAS6040, National, 01/01/2005 to 31/12/2009
• Head Coordinator, Faculty, 01/10/2002 to 31/08/2013 (Master of Clinical Oncology programme)
• Head of Department, Faculty, 01/08/2000 to 31/08/2013 (Current appointment till end August 2013)

---

• Clinical Oncology Which Covers All Aspects of Non-Surgical Treatment Modalities for Cancer Patients in Particular With Radiotherapy, Cytotoxics, Hormones and Biologics. Tumour Site Specialization Includes Breast,Lung, Brain, Lymphoproliferative Tissue, Paediatrics and Skin.

---

Article in Academic Journals

Proceeding

Others

• TROIKA study. Neoadj and adjuvant trastuzumab vs biosimilar in HER 2 positive EBC, Principal Investigator(PI), 2018 - 2023, International Funding
  
• MK3475-355 A Randomized, Double-Blind Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Inoperable Locally Recurrent or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355), Principal Investigator(PI), 2016 - 2019, MSD
  
• A randomised open label phase 3 study of single agent pembrolizumab vs single agent chemo per physician's choice for metastatic triple negative breast cancer-[KEYNOTE-119 study], Principal Investigator(PI), 2015 - 2018, MSD
  
• A Prospective Cohort Study of Patients with Malignant Cord Compression, Co-Investigator, 2014 - 2015, NUS
  
• A Phase III Randomised, Double-Blind,Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting, Co-Investigator, 2014 - 2016, Samsung Bioepis
  
• Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer, Co-Investigator, 2013 - 2015, NONE
  
• Phase II randomized study of docetaxel with or without low-dose, short course sunitinib in the treatment of advanced solid tumors., Co-Investigator, 2013 - 2015, NONE
  
• JACOB study:A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating The Efficacy and Safety of Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patient with HER-2 Positive Metastatic Gastroesophageal Junction and Cancer, Principal Investigator(PI), 2013 - 2015, Roche
  
• Oral Cancer Research: Diagnostic And Biobanking Services, Consultant, 2013 - 2015, Geran Penyelidikan Universiti Malaya (UMRG Programme) - HTM (Wellness), (University)
  
• ABI-PRO- 3002 A phase 3, randamized, double-blind,placebo-controlled study of abiraterone acetate)JNJ-212082) plus prednisone in asymtomic ormildly symptomatic patients with metastaticcastration-resistant prostate cancer, Co-Investigator, 2012 - 2017, Quintiles Janseen Cilaq, (University)
  
• Biobanking of Oral Cancers: An Assessment of Survival, Clinicopathological Parameters, Management Strategies Nutrition and Genetic Susceptibility of Patients, Co-Investigator, 2011 - 2016, High Impact Research (HIR), (University)
  
• Lapatinib study Phase II open-labelstudy of preoperativeweeklypac55 litaxel and carboplatinwithlapatinib (Tykerb ) in patientswith ErB2-positive stage I-III Breastc ncer, Co-Investigator, 2011 - 2013, High Impact Research (HIR), (University)
  
• HKI 3004 Adjuvant breast cancer study in HER2 positive patients using neratinib., Principal Investigator(PI), 2010 - 2016, Pfizer, (University)
  
• The Establishment of In-vitro Standard Dose Calibration Curve with High Energy X-ray and Measurement of The Equivalent Dose In Cancer Patients Treated with Radiotherapy Using Biological Dosimetry Technique, Principal Investigator(PI), 2010 - 2011, Postgraduate Research Grant(PPP), (University)
  
• AGILE Axitinib in metastatic renal cell carcinoma patients., Co-Investigator, 2010 - 2015, Pfizer, (University)
  
• Phase 3 open label first line treatment for HER2 positive breast cancer comparing Paclitaxel plus herceptin vs Paclitaxel plus Neratinib., Co-Investigator, 2010 - 2016, Pfizer, (University)
  
• D- CARE A Randomised Double- Blind, Placebo- Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence, Principal Investigator(PI), 2010 - 2020, Amgen, (University)
  
• ASCOLT Aspirin in treating patients with Dukes stage C colon or rectal cancer, or high risk Dukes stage B colon cancer that has been completely removed by surgery., Co-Investigator, 2010 - 2026, NCC Singapore, (University)
  
• ASPECCT Panitumumab vs cetuximab for the third line treatment of advanced colorectal cancer., Co-Investigator, 2010 - 2012, Amgen, (University)
  
• 2009AG-013736 (Axitinib) as Second Line Therapy for Asian Patients with Metastatic Renal Cell Cancer, Co-Investigator, 2009 - 2011, Pfizer, (University)
  
• LUME-Lung 2 An international, multi-centre phase III randomised controlled trial for second line treatment of recurrent, advanced non-small cell lung cancer, comparing pemetrexed + placebo versus pemetrexed + BIBF1120 (a multi-targeted tyrosine kinase inhibitor)., Principal Investigator(PI), 2009 - 2012, Boehringer-Ingelheim, (University)
  
• An international multi-centre phase III randomised controlled trial of first line treatment of advanced renal cell carcinoma, comparing bevacizumab + interferon-alpha versus bevacizumab + torisel., Co-Investigator, 2008 - 2012, Wyeth, (University)
  
• A Phase 2 Biomarker identification Trial for Erlotinib in patients with Advanced Pancreatic carcinoma (MARK study), Principal Investigator(PI), 2008 - 2011, Roche, (University)
  
• A multinational, randomised, open-label, phase 3 study of sunitinib malate vs sorafenib in patients with advanced hepatocellular carcinoma., Co-Investigator, 2008 - 2011, Pfizer, (University)
  
• Phase 3b, randomised, open-label study of Bevacizumab + Temsirolimus vs Bevacizumab + Interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma., Co-Investigator, 2008 - 2012, Wyeth, (University)
  
• A prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy. (SHARE Study), Co-Investigator, 2008 - 2010, Short Term Research Fund (Vote F)(PJP), (University)
  
• Induction and concurrent chemoradiation with cetuximab for treatment of locally advanced Nasopharyngeal Carcinoma, Co-Investigator, 2008 - 2012, Geran Penyelidikan Universiti Malaya (UMRG), (University)
  
• A Prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy (SHARE Study), Co-Investigator, 2008 - 2010, Geran Penyelidikan Universiti Malaya (UMRG), (University)
  
• Clinical trials any solid tumour in particular breast cancer.
  
• BEATRICE, Principal Investigator(PI), 2008 - 2014, Genentech, (University)
  
• A Phase II, Open-label, Randomised, Multicenter Trial of GW786034 (Pazopanib) in combination with Lapatinib (GW 572016) compared to Lapatinib alone as first line therapy in subjects with advanced or metastatic breast cancer with erb-B2 FISH positive tumours., Co-Investigator, 2007 - 2008, GSK, (University)
  
• A phase 3 multicentre, randomised, placebo- controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer., Co-Investigator, 2007 - 2010, Genentech, (University)
  
• Development of Risk Models and Management Strategies for Oral Cancer, Co-Investigator, 2007 - 2015, ScienceFund, (University)
  
• A multi-institutional study on the clinical outcome of patients with nasopharyngeal carcinoma (NPC) and the establishment of a Malaysian NPC tissue bank., Co-Investigator, 2007 - 2008, MOH, (University)
  
• SATURN/TITAN- A Multicentre, double blind randomized phase 3 study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented or advanced or recurrent or metastatic NSCLC who have not experienced disease progression or unacceptable toxicity during chemotherapy, Principal Investigator(PI), 2006 - 2011, Roche, (University)
  
• A Phase III trial of novel Epothilone BMS-247550 plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant., Principal Investigator(PI), 2005 - 2008, BMS, (University)
  
• Oral cancer and precancer in Malaysia-risk factors, prognostic markers, genetic expression and impact on quality of life., Co-Investigator, 2004 - 2015, IRPA, (University)
  
• Phase II, open label study of SB-715992 in subjects with advanced or metastatic breast cancer., Co-Investigator, 2004 - 2008, GSK, (University)
  
• Concurrent weekly Cisplatin and radiotherapy for advanced cervical cancer., Co-Investigator, 2003 - 2008, FNCA, Japan, (University)
  
• Randomised Phase 2 trial of Gemcitabine combined with a Taxane for metastatic breast cancer., Principal Investigator(PI), 2001 - 2003, Eli Lilly, (University)
  

---

• Collaborations of Radiation Oncology in Asia, Discussant, 2016-2016, JASTRO
• MEASUREMENT OF BLADDER VOLUME VARIATIONS USING PORTABLE ULTRASOUND EQUIPMENT: INTRODUCTION OF DRINKING PROTOCOL, 2013-2013, BIIJ
• Eribulin in breast cancer treatment, Consultant, 2013-2013, Eisai Malaysia Sdn Bhd
• The treatment outcome of radical radiotherapy in laryngeal cancer, Article Reviewer, 2013-2013, BIIJ
• Erlotinib in first line EGFR mutation positive NSCLC, Consultant, 2012-2012, Roche
• Head of panel of judges for oral presentations at ASCOMOS 2012, 2012-2012, Malaysian Oncological Society
• Association of creatinine clearance with neutropenia in breast cancer patients undergoing chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC), Article Reviewer, 2012-2012, MJM
• Radiation Oncology training in Malaysia, Consultant, 2012-2012, IAEA
• Penilaian ubat-ubatan kemoterapi, Ajk Teknikal, 2012-2012, UMMC
• Radioimmunotherapy-Based Treatment of Cancer, Article Reviewer, 2011-2011, BIIJ
• Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer, Article Reviewer, 2009-2009, BIIJ
• Asia Pacific Cancer Conference 2011, Organising Committee, 2008-2011, Malaysian Oncological Society
• Medulloblastoma: Cranial spinal junctional techniques., Article Reviewer, 2008-2008, BIIJ
• Poster presentations MOS 2008, Poster Judge, 2008-2008, Malaysian Oncological Society
• International Atomic Energy Agency (IAEA) Project RCA RAS 6040 Improvement in Quality of Radiotherapy for Frequent Cancers in the Region ., Project Coordinator, 2005-2009, International Atomic Energy Agency (IAEA)
• Bachelor in Medical Sciences (Diagnostic Imaging)(UKM) Bachelor in Medical Sciences (Radiotherapy)(UKM) PhD(Diagnostic Imaging)(UKM) PhD(Radiotherapy)(UKM), Committee Member, 2003-2003, UKM
• National cancer registry, Advisory Committee, 2003-2007, Ministry of Health
• 37th Malaysia-Singapore Congress of Medicine, Scientific Committee, 2003-2003, Academy of Medicine
• Bachelor in Medical Sciences (Diagnostic Imaging)(UKM) Bachelor in Medical Sciences (Radiotherapy)(UKM) PhD(Diagnostic Imaging)(UKM) PhD(Radiotherapy)(UKM), Committee Member, 2003-2003, UKM
• Annual Scientific meetings, Committee Member, 2001-2003, Malaysian Oncological Society
• MOS Annual Scientific Meeting, Chairman Of Scientific Committee, 2001-2001, Malaysian Oncological Society

---

• Certifcate of Appreciation, Faro, 2019, (International)
• Certificate of Appreciation, Faculty of Medicine,UM, 2019, (University)
• Appreciation Letter, Faro 2018 Organising Committee, 2018, (International)
• Live Surgery Iort Workshop, College of Surgeons and Academy of Medicine Malaysia, 2017, (National)
• Certificate of Appreciation, Ummc, 2017, (National)
• Letter of Appreciation, Universiti Malaya, 2016, (University)
• Certificate of Appreciation, Maspho, 2016, (National)
• Certificate of Appreciation, Malaysian Psychiatric Association, 2016, (National)
• Certificate of Excellent Service, University Malaya, 2014, (University)
• Appreciation, Ummc, 2014, (Community)
• Khidmat Setia 20 Award, 2013
• Excellence Service Award, University Malaya, 2012, (University)
• Appreciation, Iaea, 2012, (National)
• Anugerah Khidmat Cemerlang, Universiti Malaya, 2012, (University)
• Excellence Service Award, University Malaya, 2009, (University)
• Anugerah Khidmat Cemerlang, Universiti Malaya, 2009, (University)
• Eskpo Penyelidikan, Rekacipta Dan Inovasi UM 2009, Universiti Malaya, 2009, (University)
• Certificate of Excellent Service, University Malaya, 2007, (University)
• Appreciation, Dept of Biomedical Imaging, Ummc, 2007, (University)
• Appreciation, National Cancer Registry, 2007, (National)
• Excellence Service Award, University Malaya, 2006, (University)
• Anugerah Khidmat Cemerlang, Universiti Malaya, 2006, (University)
• Bronze Medal for The Category of Fundamental Research: Oxidative Stress Biomarkers in Breast Cancer. Eskpo Penyelidikan, Rekacipta Dan Inovasi 2006, 18-20 Julai, Universiti Malaya, 2006, (University)
• Certificate of Excellent Service, University Malaya, 2005, (University)
• Gold Medal for The Category of Invention & Innovation Sempena Eskpo Penyelidikan, Rekacipta Dan Inovasi 2005, 14-17 Jun. Oral Cancer Database Software- Real and Virtual Tumor Bank System (Ocds/Rvtbs)- An Aid for Multicenter Studies., Universiti Malaya, 2005, (University)
• Appreciation, Ministry of Health, 2004, (National)
• Appreciation, Mitc, Ummc, 2004, (University)
• Appreciation, Moh, 2004, (National)
• Excellence Service Award, University Malaya, 2003, (University)
• Appreciation, National Cancer Registry, 2003, (National)
• Anugerah Khidmat Cemerlang, Universiti Malaya, 2003, (University)
• Anugerah Khidmat Cemerlang, Universiti Malaya, 2002, (University)
• Anugerah Khidmat Cemerlang, Universiti Malaya, 2001, (University)

---

---

• National Project Coordinator forRCA/IAEA RAS6086 project, IAEA, Coordinator, 2019-2019, (International)
• RCA-IAEA project RAS6086 - Strengthening cancer management programmes in RCA states parties through collaboration with national and regional radiation oncology societies., IAEA, Coordinator, 2018-2018, (National)
• Evaluate the suitability of eribulin in patients who have failed one line of chemo in the advanced metastatic setting., Drug Control Authority, MOH Malaysia, Expert Advisor, 2018-2018, (National)
• Evaluate the suitability of TS-1 tablet in terms of bioequivalence as compared to TS-1 capsule to be used for the same clinical indications., DCA, MOH, Expert Advisor, 2017-2017, (National)
• Evaluate the suitability of cyramza in the treatment of stomach/GOJ tumours, colorectal and NSCLC for the purpose of registration., National Pharmaceutical Control Bureau, MOH Malaysia, Expert Advisor, 2016-2016, (National)
• Evaluate the suitability of tegafur in the treatment of colorectal cancer for the purpose of additional indication approval., Drug Control Authority Ministry of Health Malaysia, Expert Advisor, 2016-2016, (National)
• Evaluate the suitability of afinitor in the treatment of advanced renal cell carcinoma in patients with disease progression following treatment with anti VEGF, Drug Control Authority, Ministry of Health, Malaysia, Expert Advisor, 2016-2016, (National)
• Evaluate the suitability of tegafur in the treatment of pancreatic cancer for the purpose of additional indication approval., Drug Control Authority Ministry of Health Malaysia, Expert Advisor, 2016-2016, (National)
• Evaluate the suitability of tegafur in the treatment of NSCLC for the purpose of additional indication approval., Drug Control Authority Ministry of Health Malaysia, Expert Advisor, 2016-2016, (National)
• Evaluate suitability of research project/proposal for consideration of sciencefund(MOSTO) research grant, Universiti Malaya, Evaluator, 2016-2016, (University)
• Evaluate suitability of nindetanib esilate in advanced NSCLC for the purpose of new drug registration., Pihak Berkuasa Kawalan Dadah Biro Pengawalan Farmaseutikal Kebangsaan Kementerian Kesihatan Malaysia, Expert Advisor, 2015-2015, (National)
• Evaluate suitability of vismodegib in advanced basal cell carcinoma for the purpose of new drug registration., Pihak Berkuasa Kawalan Dadah Biro Pengawalan Farmaseutikal Kebangsaan Kementerian Kesihatan Malaysia, Expert Advisor, 2015-2015, (National)
• Root cause analysis, UMMC, Committee Member, 2013-2013, (Hospital Level)
• Penilaian ubat-ubatan kimoterapi, Pusat perubatab Universiti Malaya, Committee Member, 2012-2012, (University)
• Radiation oncology curriculum in developing countries, IAEA, Consultant, 2012-2012, (International)
• Clinical Oncology Specialty Committee, Universiti Malaya, Chairman, 2009-present, (National)
• Organising Committee for APCC 2011, Malaysian Oncological Society, Committee Member, 2008-present, (National)
• International Atomic Energy Agency (IAEA) Project Coordinator for project RCA RAS 6040 Improvement in Quality of Radiotherapy for Frequent Cancers in the Region., IAEA, Coordinator, 2005-2009, (International)
• To give input with regards to the conduct and management of clinical trials and in particular industry sponsored trials managed by Clinical Investigation Centre, UM, Clinical Investigation Centre, Faculty of Medicine , UM, Committee Member, 2005-Present, (University)
• Structuring, data collection, analysis and report writing, National Cancer Registry, Advisor, 2003-2007, (National)
• Medical Advisory Committee member. Advise on clinical issues at UMMC., UMMC, Committee Member, 2001-Present, (University)

---

• IMPACT OF PHYSICAL ACTIVITY ON PROGNOSIS AND QUALITY OF LIFE OF BREAST CANCER PATIENTS IN MyBCC STUDY, Masters Research Project ,  (2020 - 2020)
• Role of vitamin D in preventing colororectal carcinogenesis: Systemayic review, Article In Journal ,  (2020 - 2020)
• Mutation profile of breast cancer in Malaysian patients, Article In Journal ,  (2020 - 2020)
• Logbook and continuous assessment, Final Exam Master Of Clinical Oncology ,  (2019 - 2019)
• All Trans Retinoic Acid (ATRA) Inhibits Telomerase Expression of BeWo Choriocarcinoma Cell (ATCC CCL-98), Article In Journal ,  (2019 - 2019)
• Treatment outcome of brain metastases in UMMC., Thesis ,  (2019 - 2019)
• Exam script marker, Master Of Clinical Oncology Part 1 Exam ,  (2019 - 2019)
• Marking Part 2 COQ exam scripts. Examiner for Final Examination, Master Of Clinical Oncology Exam ,  (2019 - 2019)
• Jawatankuasa Pemeriksa bagi Peperiksaan ljazah Sarjana Sains Perubatan secara Penyelidikan /Kursus dan Penyelidikan (bagi komponen penyelidikan) i)Berkaitan dengan peperiksaan disertasi, menimbang laporan pemeriksa di atas disertasi seorang calon dan mengambil sesuatu keputusan termasuk mengenai tahap pencapaian disertasi itu ; ii) Dalam keadaan tertentu Jawatankuasa Pemeriksa boleh menjalankan peperiksaan viva dan / atau ujian lain difikirkan sesuai ; dan iii) Melaporkan kepada Senat mengenai apa-apa perkara yang berkaitan dengan mutu dan/atau perjalanan sesuatu peperiksaan., Thesis ,  (2019 - 2019)
• The Great Masquerade: Empyema Thoracis as an Unusual Presentation of Primary Lung Malignancy, Article In Journal ,  (2018 - 2018)
• Intracranial angiomatoid Fibrous histiocytoma with Hodgkin lymphoma, Article In Journal ,  (2018 - 2018)
• Comparison of the seventh and eight editions of the UICC/AJCC staging system for NPC; analysis of 1317 patients treated with IMRT at two centres, Article In Journal ,  (2017 - 2017)
• Outcome of patients with cord compression treated in UMMC. Master of Clinical Oncology Final Exam, Thesis ,  (2017 - 2017)
• Marking MCO Part 1 exam scripts, Exam Script ,  (2017 - 2017)
• Review and select abstracts for FARO 2017 scientific meeting, Abstracts ,  (2017 - 2017)
• Chemotherapy for metastatic colon cancer -No effect on survival when the dose is reduced due to side-effects. BMC cancer, Article In Journal ,  (2017 - 2017)
• Ref.: Ms. No. MJM-D-17-00148 Breast Ductal Carcinoma to Metaplastic Carcinoma- A Change in Cancer Morphology - A Case Report and Literature Review The Medical Journal of Malaysia, Article In Journal ,  (2017 - 2017)
• "Stress levels during the journey of cancer treatment", Article In Journal ,  (2017 - 2017)
• Lapatinib, trastuzumab and Capecitabine prolonged the survival of HER2-positive gastric cancer with leptomeningeal carcinomatosis: a case report., Article In Journal ,  (2017 - 2017)
• Marking of exam scripts for Master of Clinical Oncology Part 1 May 2017 Exam, Exam Script Marker ,  (2017 - 2017)
• Examiner for MD degree. Title of thesis: Management of psychological distress in cancer patients. MHB130001, Thesis ,  (2017 - 2017)
• Evaluation of research proposal under FRGS grant application, Frgs Grant ,  (2017 - 2017)
• Relapsed Lymphoma Mimicking Venous Ulcer : A Case report for MJM, Article In Journal ,  (2017 - 2017)
• Peperiksaan OSCE Stage 2 MBBS - RSA 1, Osce Stage 2 Mbbs Exam ,  (2017 - 2017)
• Pretreatment Expression of Blood and Tissue Biomarkers as a Predictor of Tumor Response After Neoadjuvant Chemoradiation in Rectal Cancer, Article In Journal ,  (2016 - 2016)
• Review research abstracts submitted for FARO 2016. Provide scoring for each as per guideline from organising commitee., Abstracts ,  (2016 - 2016)
• Evaluate the suitability of the following article for publication in BMC Cancer journal: Chemotherapy on metastatic colon cancer:No effect on survival when dose is reduced due to side-effects., Article In Journal ,  (2016)
• Medical Journal Malaysia: Gastric ulcer than turned out to be metastasis of a synovial sarcoma: A case report and literature review., Article In Journal ,  (2016)
• Management of psychological distress in cancer patients: Focus on brief mindful therapy, Phd Seminar Proposal ,  (2016)
• Chemotherapy Induced Neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort Study, Article In Journal ,  (2016)
• Evaluate suitability of research proposal/project for consideration of sciencefund (MOSTI) research grant, Project ,  (2016)
• Triple negative breast cancer survival and prognostic factors., Thesis ,  (2016)
• Master of Clinical Oncology Part 1, 2 and Final Exams, Prepare Exam Questions And Mark Exam Scripts ,  (2016)
• Treatment Of heavily pre-treated metastatic breast cancer with Eribulin: First local experience in Sabah., Article In Journal ,  (2016)
• marking exam scripts and viva voce, Master Of Clinical Oncology ,  (2015)
• Palliative to curative treatment: A case of stage 4 mucinous adenocarcinoma successfully treated with metronomic capecitabine in combination with bevacizumab and surgery., Article In Journal ,  (2015 - 2015)
• Symptoms burden and QoL. Comparison between CAM and non-CAM users during breast cancer chemotherapy in 2 public hospitals in Malaysia., Thesis ,  (2015 - 2015)
• Editorial board member for International Journal of Recent Research in Life Sciences (IJRRLS), Article In Journal ,  (2014)
• Survival of primary lung cancer patients treated in Brunei darussalam, Article In Journal ,  (2013 - 2013)
• Metastatic melanoma to the stomach; a case report, Article Reviewer ,  (2013 - 2013)
• The treatment outcome of radical radiotherapy in laryngeal cancer., Article Reviewer ,  (2013 - 2013)
• JUMMEC Case study: Squinting eyes: A presenting complaint in a young adult with glioblastome multiforme., Article Reviewer ,  (2013 - 2013)
• MJM Chemotherapy extravasation at Hospital Pulau Pinang Malaysia, Article Reviewer ,  (2013 - 2013)
• Master of Clinical Oncology Part 1,2 and Final Exam, Mark Exam Scripts And Conduct Clinical Exam ,  (2013)
• Appointed as external assessor from UCSI University to assess suitability of an academic staff from UCSI for promotion from assoc. prof. to full prof., To Assess Suitability Of Candidate For Promotion ,  (2013 - 2013)
• MEASUREMENT OF BLADDER VOLUME VARIATIONS USING PORTABLE ULTRASOUND EQUIPMENT: INTRODUCTION OF DRINKING PROTOCOL, Article In Journal ,  (2013 - 2013)
• Association of creatinine clearance with neutropenia in breast cancer patients undergoing chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC), Article In Journal ,  (2012 - 2012)
• Induction chemotherapy with paclitaxel, ifosfamide and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer., Article In Journal ,  (2009 - 2009)
• Advanced Diploma in Nursing Oncology (UM), Programme Evaluator ,  (2008 - 2008)
• Bachelor in Medical Sciences (Diagnostic Imaging)(UKM) Bachelor in Medical Sciences (Radiotherapy)(UKM) PhD(Diagnostic Imaging)(UKM) PhD(Radiotherapy)(UKM), Academic Programme Evaluator ,  (2008 - 2008)
• Poster presentations, Judge For Poster Presentations ,  (2008 - 2008)
• Medulloblastoma: Cranial spinal junctional techniques., Article Reviewer ,  (2008 - 2008)
• Master of Clinical Oncology Part 1 Exam, Internal Examiner ,  (2006)

---

• SEAROG Council Advisor, (International), 01/01/2019 until 31/12/2019
• FARO Council member representing Malaysian Oncological Society and Malaysia, (International), 01/01/2019 until 31/12/2019
• Breast cancer public forum, (Community), 18/10/2014 until 18/10/2014
• SMK Seksyen 9 Shah Alam Niners A+ committee member, (Community), 01/07/2013 until 12/10/2013
• Women's Integration Society, (Local), 01/01/2002 until  

---

• Master of Clinical Oncology Programme Syllabus, literary work, 08/11/2013, (UNIVERSITY)

---

POST GRADUATE STUDENT
(Name of Degree), (Name of Candidates), (Title of Thesis), (Academic Session)

FIRST DEGREE/DIPLOMA/PRE-DEGREE
(Course Title), (Academic Session), (No. of Candidates)

---